Cargando…
The paradox of immunosuppressants and COVID-19
Lessons learned from a large registry analysis show worse COVID-19 outcomes for patients previously exposed to glucocorticoids https://bit.ly/306rNrk
Autores principales: | Cheng, Guang-Shing, Evans, Scott E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607867/ https://www.ncbi.nlm.nih.gov/pubmed/34795039 http://dx.doi.org/10.1183/13993003.02828-2021 |
Ejemplares similares
-
The Obesity Paradox in Infections and Implications for COVID-19
por: Lavie, Carl J., et al.
Publicado: (2021) -
Does Obesity Paradox Exist in COVID-19 Mortality?
por: Kim, JungHwan
Publicado: (2022) -
Pandemic, power and paradox: Improvising as the New Normal during the
COVID-19 crisis
por: Simpson, Ace Volkmann, et al.
Publicado: (2023) -
Immunosuppression for COVID-19: repurposing medicines in a pandemic
por: Shivakumar, Senthuran, et al.
Publicado: (2020) -
To immunosuppress: whom, when and how? That is the question with COVID-19
por: Winthrop, Kevin L, et al.
Publicado: (2020)